Genetic Imaging Study With [tc-(99m)] Trodat-1 Spect in Adolescents With Adhd Using Oros-Methylphenidate

dc.contributor.author Akay, Aynur Pekcanlar
dc.contributor.author Kaya, Gamze Capa
dc.contributor.author Kose, Samet
dc.contributor.author Yazicioglu, Cigdem Eresen
dc.contributor.author Erkuran, Handan Ozek
dc.contributor.author Guney, Sevay Alsen
dc.contributor.author Oguz, Kaya
dc.date.accessioned 2023-06-16T14:11:22Z
dc.date.available 2023-06-16T14:11:22Z
dc.date.issued 2018
dc.description.abstract Aim: To examine theeffects on the brain of 2-month treatment withamethylphenidate extended-release formulation (OROS-MPH) using [Tc-(99m)] TRODAT-1SPECT in a sample of treatment-naive adolescents with Attention Deficit/Hyperactivity Disorder (ADHD). In addition, to assess whether risk alleles (homozygosity for 10-repeat allele at the DAT1 gene were associated with alterations in striatal DAT availability. Methods: Twenty adolescents with ADHD underwent brain single-photon emission computed tomography (SPECT) scans with [Tc-(99m)] TRODAT-1 at baseline and two months after starting OROS-MPH treatment with dosages up to 1 mg/kg/day. Severity of illness was estimated using the Clinical Global Impression Scale (CGI-S) and DuPaul ADHD Rating Scale-Clinician version (ARS) before treatment,1 month and 2 months after initiating OROS-MPH treatment. Results: Decreased DAT availability was found in both the right caudate (pretreatment DAT binding: 224.76 +/- 33.77, post-treatment DAT binding: 208.86 +/- 28.75, p = 0.02) and right putamen (pre-treatment DAT binding: 314.41 +/- 55.24, post-treatment DAT binding: 285.66 +/- 39.20, p = 0.05) in adolescents with ADHD receiving OROS-MPH treatment. Adolescents with ADHD who showed a robust response to OROS-MPH (n = 7) had significantly greater reduction of DAT density in the right putamen than adolescents who showed less robust response to OROS-MPH (n = 13) (p = 0.02). However, between-group differences by treatment responses were not related with DAT density in the right caudate. Risk alleles (homozygosity for the 10-repeat allele of DAT1 gene) in the DAT1 gene were not associated with alterations in striatal DAT availability. Conclusion: Two months of OROS-MPH treatment decreased DAT availability in both the right caudate and putamen. Adolescents with ADHD who showed a robust response to OROS-MPH had greater reduction of DAT density in the right putamen. However,our findings did not support an association between homozygosity for a 10-repeat allele in the DAT1 gene and DAT density, assessedusing[Tc-(99m)] TRODAT-1SPECT. en_US
dc.description.sponsorship Dokuz Eylul University Research Committee [2008132]; Fogarty MH/DD program; Institute of Nuclear Energy Research (INER-Taipei, Taiwan) en_US
dc.description.sponsorship This study was partially supported by Dokuz Eylul University Research Committee (2008132), Fogarty MH/DD program and the Institute of Nuclear Energy Research (INER-Taipei, Taiwan). en_US
dc.identifier.doi 10.1016/j.pnpbp.2018.04.008
dc.identifier.issn 0278-5846
dc.identifier.issn 1878-4216
dc.identifier.scopus 2-s2.0-85046665865
dc.identifier.uri https://doi.org/10.1016/j.pnpbp.2018.04.008
dc.identifier.uri https://hdl.handle.net/20.500.14365/1368
dc.language.iso en en_US
dc.publisher Pergamon-Elsevier Science Ltd en_US
dc.relation.ispartof Progress in Neuro-Psychopharmacology & Bıologıcal Psychıatry en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject ADHD en_US
dc.subject DAT1 gene en_US
dc.subject [Tc-(99m)] TRODAT-1 SPECT en_US
dc.subject OROS-methylphenidate en_US
dc.subject Deficit Hyperactivity Disorder en_US
dc.subject Dopamine-Transporter Gene en_US
dc.subject Attention-Deficit/Hyperactivity Disorder en_US
dc.subject Tc-99m-Trodat-1 Spect en_US
dc.subject Parkinsons-Disease en_US
dc.subject Children en_US
dc.subject Association en_US
dc.subject Adults en_US
dc.subject Psychostimulants en_US
dc.subject Availability en_US
dc.title Genetic Imaging Study With [tc-(99m)] Trodat-1 Spect in Adolescents With Adhd Using Oros-Methylphenidate en_US
dc.title.alternative Tc- 99m] Trodat-1 Spect in Adolescents With Adhd Using Oros-Methylphenidate en_US
dc.type Article en_US
dspace.entity.type Publication
gdc.author.id Baykara, Huseyin Burak/0000-0002-1530-0159
gdc.author.id Kose, Samet/0000-0003-0841-004X
gdc.author.id Yazıcıoğlu, Çiğdem Eresen/0000-0001-9155-6589
gdc.author.id Erkuran, Handan Özek/0000-0003-3775-0211
gdc.author.id Alşen, Sevay/0000-0003-1064-6115
gdc.author.id Rohde, Luis Augusto P/0000-0002-4552-4188
gdc.author.id Oguz, Kaya/0000-0002-1860-9127
gdc.author.scopusid 55667400100
gdc.author.scopusid 55662831600
gdc.author.scopusid 57536563900
gdc.author.scopusid 56251903000
gdc.author.scopusid 57192301366
gdc.author.scopusid 57194021762
gdc.author.scopusid 54902980200
gdc.author.wosid Baykara, Huseyin Burak/AAH-4898-2020
gdc.author.wosid AKAY, AYNUR/O-7335-2019
gdc.author.wosid Yazıcıoğlu, Çiğdem Eresen/P-4539-2019
gdc.author.wosid Kose, Samet/Q-2324-2017
gdc.author.wosid Erkuran, Handan Özek/G-1490-2019
gdc.author.wosid Alşen, Sevay/HJP-9007-2023
gdc.author.wosid Rohde, Luis Augusto P/A-6426-2008
gdc.bip.impulseclass C5
gdc.bip.influenceclass C5
gdc.bip.popularityclass C4
gdc.coar.access metadata only access
gdc.coar.type text::journal::journal article
gdc.collaboration.industrial false
gdc.description.department İzmir Ekonomi Üniversitesi en_US
gdc.description.departmenttemp [Akay, Aynur Pekcanlar; Guney, Sevay Alsen; Baykara, Burak; Emiroglu, Neslihan Inal; Miral, Suha] Dokuz Eylul Univ, Dept Child & Adolescent Psychiat, Izmir, Turkey; [Kaya, Gamze Capa; Eren, Mine Sencan; Ertay, Turkan; Durak, Hatice] Dokuz Eylul Univ, Dept Nucl Med, Izmir, Turkey; [Kose, Samet] H Kalyoncu Univ, Dept Psychol, Gaziantep, Turkey; [Kose, Samet] Univ Texas Houston, Med Sch Houston, Ctr Neurobehav Res Addict, Houston, TX USA; [Yazicioglu, Cigdem Eresen; Kizildag, Sefa; Ozsoylu, Dua] Dokuz Eylul Univ, Dept Mol Biol & Genet, Izmir, Turkey; [Erkuran, Handan Ozek] Dr Behcet Uz Pediat Pediat Surg Res & Training Ho, Deparment Child & Adolescent Psychiat, Izmir, Turkey; [Oguz, Kaya] Izmir Univ Econ, Dept Comp Engn, Izmir, Turkey; [Keskin, Duygu; Gonul, Ali Saffet] EgianUniv, Dept Psychiat, Izmir, Turkey; [Rohde, Luis Augusto] Univ Fed Rio Grande do Sul, Dept Psychiat, Porto Alegre, RS, Brazil; [Rohde, Luis Augusto] Hosp Clin Porto Alegre, ADHD Program, Porto Alegre, RS, Brazil en_US
gdc.description.endpage 300 en_US
gdc.description.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
gdc.description.scopusquality Q1
gdc.description.startpage 294 en_US
gdc.description.volume 86 en_US
gdc.description.wosquality Q1
gdc.identifier.openalex W2799969460
gdc.identifier.pmid 29684537
gdc.identifier.wos WOS:000436416800034
gdc.index.type WoS
gdc.index.type Scopus
gdc.index.type PubMed
gdc.oaire.diamondjournal false
gdc.oaire.impulse 3.0
gdc.oaire.influence 2.6059934E-9
gdc.oaire.isgreen false
gdc.oaire.keywords Male
gdc.oaire.keywords Adolescent
gdc.oaire.keywords OROS-methylphenidate
gdc.oaire.keywords ADHD
gdc.oaire.keywords Humans
gdc.oaire.keywords Genetic Predisposition to Disease
gdc.oaire.keywords DAT1 gene
gdc.oaire.keywords [Tc-(99m)] TRODAT-1 SPECT
gdc.oaire.keywords Psychiatric Status Rating Scales
gdc.oaire.keywords Tomography, Emission-Computed, Single-Photon
gdc.oaire.keywords Brain Mapping
gdc.oaire.keywords Dopamine Plasma Membrane Transport Proteins
gdc.oaire.keywords Homozygote
gdc.oaire.keywords Brain
gdc.oaire.keywords Organotechnetium Compounds
gdc.oaire.keywords Treatment Outcome
gdc.oaire.keywords Attention Deficit Disorder with Hyperactivity
gdc.oaire.keywords Delayed-Action Preparations
gdc.oaire.keywords Methylphenidate
gdc.oaire.keywords Central Nervous System Stimulants
gdc.oaire.keywords Female
gdc.oaire.keywords Radiopharmaceuticals
gdc.oaire.keywords Tropanes
gdc.oaire.popularity 6.340506E-9
gdc.oaire.publicfunded false
gdc.oaire.sciencefields 03 medical and health sciences
gdc.oaire.sciencefields 0302 clinical medicine
gdc.openalex.collaboration International
gdc.openalex.fwci 0.4875
gdc.openalex.normalizedpercentile 0.65
gdc.opencitations.count 8
gdc.plumx.crossrefcites 8
gdc.plumx.mendeley 38
gdc.plumx.pubmedcites 5
gdc.plumx.scopuscites 7
gdc.scopus.citedcount 7
gdc.virtual.author Oğuz, Kaya
gdc.wos.citedcount 6
relation.isAuthorOfPublication 352071e4-5cb7-4239-be4d-3132ba33986c
relation.isAuthorOfPublication.latestForDiscovery 352071e4-5cb7-4239-be4d-3132ba33986c
relation.isOrgUnitOfPublication b4714bc5-c5ae-478f-b962-b7204c948b70
relation.isOrgUnitOfPublication 26a7372c-1a5e-42d9-90b6-a3f7d14cad44
relation.isOrgUnitOfPublication e9e77e3e-bc94-40a7-9b24-b807b2cd0319
relation.isOrgUnitOfPublication.latestForDiscovery b4714bc5-c5ae-478f-b962-b7204c948b70

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
407.pdf
Size:
559.87 KB
Format:
Adobe Portable Document Format